Granulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid Leukemia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Myeloid-derived suppressor cells (MDSCs) represent phenotypically heterogeneous populations that suppress tumor-specific T-cell responses. MDSCs are produced from myeloid precursors in emergent states and are increased in several hematologic malignancies. We evaluated the differences in the levels and prognostic significance of MDSCs according to the clinical status of chronic myeloid leukemia (CML). The percentages and numbers of granulocytic (g)MDSCs and monocytic (m)MDSCs in peripheral blood (PB) and bone marrow (BM) aspirates were determined by five-color flow cytometry (HLA-DR/CD11b/CD15/CD33/CD14). The median BM-gMDSC% and PB-gMDSC% of the CML group were lower than those of the complete hematologic response (CHR) and control groups (P<0.001). In the CHR group, patients with major molecular response (MMR) showed higher median BM-gMDSC% than those without MMR (P=0.039). Conversely, the PB-mMDSC number of the CML group was higher than those of the CHR and control groups (P<0.001). Patients with high PB-gMDSC number exhibited superior survival to those with low PB-gMDSC number (P=0.021), and patients with high PB-mMDSC% showed inferior survival to those with low PB-mMDSC%, but there was no statistical significance (P=0.182). Increased gMDSCs at CHR may reflect non-leukemic granulopoiesis, and a high number of PB-gMDSCs suggests better prognosis in CML. However, mMDSCs may be associated with malignant conditions and poor prognosis.
Abstract
Myeloid-derived suppressor cells (MDSCs) represent phenotypically heterogeneous populations that suppress tumor-specific T-cell responses. MDSCs are produced from myeloid precursors in emergent states and are increased in several hematologic malignancies. We evaluated the differences in the levels and prognostic significance of MDSCs according to the clinical status of chronic myeloid leukemia (CML). The percentages and numbers of granulocytic (g)MDSCs and monocytic (m)MDSCs in peripheral blood (PB) and bone marrow (BM) aspirates were determined by five-color flow cytometry (HLA-DR/CD11b/CD15/CD33/CD14). The median BM-gMDSC% and PB-gMDSC% of the CML group were lower than those of the complete hematologic response (CHR) and control groups (P<0.001). In the CHR group, patients with major molecular response (MMR) showed higher median BM-gMDSC% than those without MMR (P=0.039). Conversely, the PB-mMDSC number of the CML group was higher than those of the CHR and control groups (P<0.001). Patients with high PB-gMDSC number exhibited superior survival to those with low PB-gMDSC number (P=0.021), and patients with high PB-mMDSC% showed inferior survival to those with low PB-mMDSC%, but there was no statistical significance (P=0.182). Increased gMDSCs at CHR may reflect non-leukemic granulopoiesis, and a high number of PB-gMDSCs suggests better prognosis in CML. However, mMDSCs may be associated with malignant conditions and poor prognosis.
참고문헌 (20)
- Bueno V, "Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease", Age (Dordr), 36, pp.9729~ (2014)
- Bronte V, "Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards", Nat Commun, 7, pp.12150~ (2016)
- Youn JI, "Subsets of myeloid-derived suppressor cells in tumor-bearing mice", J Immunol, 181, pp.5791~5802 (2008)
- Talmadge JE, "History of myeloid-derived suppressor cells", Nat Rev Cancer, 13, pp.739~752 (2013)
- Korn C, "Myeloid malignancies and the microenvironment", Blood, 129, pp.811~822 (2017)
- Gabrilovich DI, "Myeloid-derived suppressor cells", Cancer Immunol Res, 5, pp.3~8 (2017)
- Veglia F, "Myeloid-derived suppressor cells coming of age", Nat Immunol, 19, pp.108~119 (2018)
- Solito S, "Myeloid‐derived suppressor cell heterogeneity in human cancers", Ann NY Acad Sci, 1319, pp.47~65 (2014)
- Giallongo C, "Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients", PloS One, 9, pp.e101848~ (2014)
- Giallongo C, "Myeloid derived suppressor cells in chronic myeloid leukemia", Front Oncol, 5, pp.107~ (2015)
- Bizymi N, "Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets", Hemasphere, 3, pp.e168~ (2019)
- Wang J, "Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells", J Immunol, 194, pp.4215~4221 (2015)
- Luyckx A, "G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells", Clin Immunol, 143, pp.83~87 (2012)
- Xu H, "The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia", Leuk Lymphoma, 61, pp.128~137 (2020)
- Youn JI, "The biology of myeloid‐derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity", Eur J Immunol, 40, pp.2969~2975 (2010)
- Nagaraj S, "Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer", Nat Med, 13, pp.828~835 (2007)
- Priceman SJ, "Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy", Blood, 115, pp.1461~1471 (2010)
- Movahedi K, "Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell – suppressive activity", Blood, 111, pp.4233~4244 (2008)
- Dolcetti L, "Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF", Eur J Immunol, 40, pp.22~35 (2010)
- Nausch N, "Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells", Blood, 112, pp.4080~4089 (2008)